
Releases
Levi & Korsinsky Opens Investigation Into Dr. Reddy’s Laboratories
Shares of Dr. Reddy's Laboratories dropped roughly 9% on July 22, 2026, following the company’s disclosure of a ₹2.4 billion provision related to out-of-spec semaglutide batches. The sudden financial hit prompted the law firm Levi & Korsinsky to launch an investigation into potential securities law violations concerning the company's prior public statements.


























